Agios carries deep quality deficiencies — free cash flow at -405% of revenue, no competitive moat, and quality well below the minimum investment threshold — while technically strong momentum and three consecutive earnings beats reflect near-term execution; the risk/reward geometry of 0.67 to 1 and short interest at 12% make this a setup to avoid absent a catalyst that substantially improves the fundamental picture.
Thesis pillars
- Elevated Institutional Skepticism→Stable
- Deep Quality Deficiency Cash Burn→Stable
- Strong Near Term Momentum→Stable
- +1 more pillar — see the Why tab for full reasoning
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $37.58: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 12%; Below-average business quality; Rich valuation.
Agios Pharmaceuticals is a commercial-stage rare hematology company with two approved medicines: PYRUKYND® (mitapivat) for PK deficiency in the U.S. and EU, and AQVESME™ (mitapivat) FDA-approved in December 2025 for thalassemia. PYRUKYND® generated $54.0 million in net product... Read more
Sell if holding. Engine safety override at $37.58: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 12%; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 90. Score 4.7/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 27d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.
About Agios Pharmaceuticals, Inc.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals' two approved medicines—PYRUKYND for PK deficiency (approved in the U.S., EU, and Great Britain) and AQVESME for thalassemia (FDA-approved December 2025)—both contain mitapivat, an oral pyruvate kinase activator. PYRUKYND generated $54.0 million in net product revenues in the year ended December 31, 2025, compared with $36.5 million in 2024 and $26.8 million in 2023. AQVESME launched commercially in late January 2026 following FDA approval and implementation of a Risk Evaluation and Mitigation Strategy to monitor hepatocellular injury risk.
Agios earns product revenue from direct U.S. sales of PYRUKYND and AQVESME, and rest-of-world royalties under two distribution agreements: the Avanzanite Agreement (European Economic Area, Switzerland, and the United Kingdom, signed June 2025) and the NewBridge Agreement (Gulf Council Countries, signed July 2024). The company retains full ownership of both approved medicines and funds their development and commercialization costs. The commercial patient population is narrow—PK deficiency affects an estimated 3,000–8,000 individuals in the U.S. and EU5, while thalassemia prevalence in those same markets is roughly 18,000–23,000. Beyond product revenue, Agios retains a 3% earn-out on vorasidenib U.S. net sales above $1.0 billion per year following the August 2024 sale of the Vorasidenib Royalty Rights to Royalty Pharma for $905.0 million. The remaining pipeline includes tebapivat for lower-risk MDS and SCD, AG-181 for phenylketonuria, and AG-236 licensed from Alnylam Pharmaceuticals targeting TMPRSS6 for polycythemia vera.
Show full overview
The next significant binary event is FDA review of the sickle cell disease application for mitapivat: the Phase 3 RISE UP trial achieved the hemoglobin response primary endpoint (40.6% response vs. 2.9% placebo, p<0.0001) but missed the co-primary annualized pain crises endpoint (p=0.1213). Agios plans a pre-supplemental NDA meeting with the FDA in the first quarter of 2026 before submitting the U.S. marketing application; regulatory acceptance of a mixed-endpoint package could expand the mitapivat franchise into a U.S. and EU5 patient population of approximately 120,000–135,000—substantially larger than either current approved indication.
See also: Healthcare · Biotechnology
From Agios Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-06Recent Developments — Agios Pharmaceuticals, Inc.
Latest news
- NEWS Reported Saturday, Agios Presents RISE UP Phase 3 Data At EHA 2026 Showing Mitapivat Achieves 40.6% Hemoglobin Response — benzinga Jun 15, 2026 positive
- NEWS JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31 — benzinga Jun 11, 2026 negative
- NEWS Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec — benzinga Jun 1, 2026 positive
- NEWS B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $40 — benzinga May 29, 2026 neutral
- NEWS Agios Pharma Says It Will Not Advance Tebapivat, Next-Gen Oral Pyruvate Kinase Activator, In Lower-Risk Myelodysplastic — benzinga May 29, 2026 negative
Generated 2026-07-06T06:50:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPYRUKYND® / AQVESME™10-K Item 1A: 'Our ability to generate meaningful revenue from PYRUKYND® and AQVESME™ will depend heavily on our successful development and commercialization of the product'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $37.58: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 12%; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 90. Prior stop was $34.95. Score 4.7/10, moderate confidence.
Take-profit target: $37.61 (+0.1% upside). Prior stop was $34.95. Stop-loss: $34.95.
Concentration risk — Product: PYRUKYND® / AQVESME™; Target reached (-5.7% upside); Quality below floor (1.6 < 4.0).
Agios Pharmaceuticals, Inc. trades at a P/E of N/A (forward -8.0). TrendMatrix value score: 2.4/10. Verdict: Sell.
16 analysts cover AGIO with a consensus score of 4.1/5. Average price target: $41.
What does Agios Pharmaceuticals, Inc. do?Agios Pharmaceuticals is a commercial-stage rare hematology company with two approved medicines: PYRUKYND® (mitapivat)...
Agios Pharmaceuticals is a commercial-stage rare hematology company with two approved medicines: PYRUKYND® (mitapivat) for PK deficiency in the U.S. and EU, and AQVESME™ (mitapivat) FDA-approved in December 2025 for thalassemia. PYRUKYND® generated $54.0 million in net product revenues in 2025 and AQVESME™ launched commercially in the United States in late January 2026.